419 related articles for article (PubMed ID: 26733306)
1. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
[TBL] [Abstract][Full Text] [Related]
2. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
Zhu H; Yun F; Shi X; Wang D
Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of IGFBP-2 improves the sensitivity of bladder cancer cells to cisplatin via upregulating the expression of maspin.
Zhu H; Yun F; Shi X; Wang D
Int J Mol Med; 2015 Aug; 36(2):595-601. PubMed ID: 26080829
[TBL] [Abstract][Full Text] [Related]
4. 5-Aza-2'-deoxycytidine enhances maspin expression and inhibits proliferation, migration, and invasion of the bladder cancer T24 cell line.
Zhang H; Qi F; Cao Y; Zu X; Chen M; Li Z; Qi L
Cancer Biother Radiopharm; 2013 May; 28(4):343-50. PubMed ID: 23570371
[TBL] [Abstract][Full Text] [Related]
5. miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro.
Lei Y; Hu X; Li B; Peng M; Tong S; Zu X; Wang Z; Qi L; Chen M
Med Sci Monit; 2014 Oct; 20():1850-7. PubMed ID: 25287716
[TBL] [Abstract][Full Text] [Related]
6. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin.
Zhang X; Zhang Y; Liu X; Fang A; Li P; Li Z; Liu T; Yang Y; Du L; Wang C
PLoS One; 2015; 10(11):e0143441. PubMed ID: 26599571
[TBL] [Abstract][Full Text] [Related]
8. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
[TBL] [Abstract][Full Text] [Related]
10. miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.
Lei Y; Li B; Tong S; Qi L; Hu X; Cui Y; Li Z; He W; Zu X; Wang Z; Chen M
PLoS One; 2015; 10(2):e0117809. PubMed ID: 25658842
[TBL] [Abstract][Full Text] [Related]
11. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).
Bunch B; Krishnan N; Greenspan RD; Ramakrishnan S; Attwood K; Yan L; Qi Q; Wang D; Morrison C; Omilian A; Bshara W; Pili R; Trump DL; Johnson C; Woloszynska A
Cell Cycle; 2019 Sep; 18(17):2055-2066. PubMed ID: 31318640
[TBL] [Abstract][Full Text] [Related]
12. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
13. Derlin-1 overexpression confers poor prognosis in muscle invasive bladder cancer and contributes to chemoresistance and invasion through PI3K/AKT and ERK/MMP signaling.
Dong Q; Fu L; Zhao Y; Tan S; Wang E
Oncotarget; 2017 Mar; 8(10):17059-17069. PubMed ID: 28178653
[TBL] [Abstract][Full Text] [Related]
14. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
[TBL] [Abstract][Full Text] [Related]
15. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
[TBL] [Abstract][Full Text] [Related]
16. Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation.
Li X; Wang H; Wang J; Chen Y; Yin X; Shi G; Li H; Hu Z; Liang X
BMC Cancer; 2016 Aug; 16():578. PubMed ID: 27485374
[TBL] [Abstract][Full Text] [Related]
17. Expression and regulation of tumor suppressor gene maspin in human bladder cancer.
Sugimoto S; Maass N; Takimoto Y; Sato K; Minei S; Zhang M; Hoshikawa Y; Jünemann KP; Jonat W; Nagasaki K
Cancer Lett; 2004 Jan; 203(2):209-15. PubMed ID: 14732229
[TBL] [Abstract][Full Text] [Related]
18. Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates.
Surowiak P; Materna V; Drag-Zalesinska M; Wojnar A; Kaplenko I; Spaczyński M; Dietel M; Zabel M; Lage H
Int J Gynecol Pathol; 2006 Apr; 25(2):131-9. PubMed ID: 16633061
[TBL] [Abstract][Full Text] [Related]
19. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
[TBL] [Abstract][Full Text] [Related]
20. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
